Molecular Basis of Tumorigenesis of Bladder Cancer and Emerging Concepts in Developing Therapeutic Targets

Overview

Journal Bladder Cancer

Publisher IOS Press

Date 2024 Jul 12

PMID 38994247

Authors

Rana M Abdeltwab

Elaria Yacoub

Ahmed H Rashad

Kyrillus S Shohdy

Affiliations

Soon will be listed here.

Abstract

Background: Advanced urothelial carcinoma (UC) is an aggressive disease whose mutagenic processes are yet to be elucidated. Targeted therapies are urgently needed, but the road from bench to bedside is slowly progressing. In this review, we discuss urothelial carcinoma etiology, along with the most recent advances in UC candidate targeted therapies.

Methodology: A comprehensive database search was performed. We aimed to review the most recent updates on UC genomics and targeted therapies. Pre-clinical as well as clinical studies were included.

Results: Our review highlights the advances in understanding the molecular basis of urothelial tumorigenesis, including smoking, chemical parasitic carcinogens, inheritance, and APOBEC3 editing enzymes. We discussed how these factors contributed to the current mutational landscape of UC. Therapeutic options for UC are still very limited. However, several promising therapeutic approaches are in development to leverage our knowledge of molecular targets, such as targeting fibroblast growth factor receptors (FGFR), DNA damage repair pathways, and HER2.

Conclusions: Blindly testing targeted therapies based on other cancer data is not sufficient. UC-specific biomarkers are needed to precisely use the appropriate drug for the appropriate population. More efforts to understand UC biology and evolution are urgently needed.

References

Jiang M, Jia K, Wang L, Li W, Chen B, Liu Y . Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharm Sin B. 2021; 11(10):2983-2994. PMC: 8546664. DOI: 10.1016/j.apsb.2021.01.003. View

Salzberg M, Borner M, Bauer J, Morant R, Rauch D, Rochlitz C . Trastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients. Eur J Cancer. 2006; 42(15):2660-1. DOI: 10.1016/j.ejca.2006.06.009. View

Bayne C, Farah D, Herbst K, Hsieh M . Role of urinary tract infection in bladder cancer: a systematic review and meta-analysis. World J Urol. 2018; 36(8):1181-1190. DOI: 10.1007/s00345-018-2257-z. View

Singh H, Liu Y, Xiao X, Lin L, Kim J, Van Hummelen P . Whole exome sequencing of urachal adenocarcinoma reveals recurrent NF1 mutations. Oncotarget. 2016; 7(20):29211-5. PMC: 5045390. DOI: 10.18632/oncotarget.8640. View

El Sayed I, Elkhwsky F, La Vecchia C, Alicandro G . The frequency of bladder cancer in Alexandria, Egypt, over the last two decades. Eur J Cancer Prev. 2017; 27(5):477-478. DOI: 10.1097/CEJ.0000000000000368. View

Moriya M, Slade N, Brdar B, Medverec Z, Tomic K, Jelakovic B . TP53 Mutational signature for aristolochic acid: an environmental carcinogen. Int J Cancer. 2011; 129(6):1532-6. DOI: 10.1002/ijc.26077. View

Murta-Nascimento C, Silverman D, Kogevinas M, Garcia-Closas M, Rothman N, Tardon A . Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk?. Cancer Epidemiol Biomarkers Prev. 2007; 16(8):1595-600. DOI: 10.1158/1055-9965.EPI-06-0743. View

Oudard S, Culine S, Vano Y, Goldwasser F, Theodore C, Nguyen T . Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. Eur J Cancer. 2014; 51(1):45-54. DOI: 10.1016/j.ejca.2014.10.009. View

Roy S, Pradhan D, Ernst W, Mercurio S, Najjar Y, Parikh R . Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma. Mod Pathol. 2017; 30(8):1133-1143. DOI: 10.1038/modpathol.2017.33. View

10.

Roberts S, Lawrence M, Klimczak L, Grimm S, Fargo D, Stojanov P . An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 2013; 45(9):970-6. PMC: 3789062. DOI: 10.1038/ng.2702. View

11.

Yang H, Liu Z, Wang Y, Li J, Li R, Wang Q . Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC. Ther Adv Med Oncol. 2020; 12:1758835920970845. PMC: 7675892. DOI: 10.1177/1758835920970845. View

12.

Carlo M, Ravichandran V, Srinavasan P, Bandlamudi C, Kemel Y, Ceyhan-Birsoy O . Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. J Clin Oncol. 2019; 38(5):406-414. PMC: 7351337. DOI: 10.1200/JCO.19.01395. View

13.

Mucci L, Hjelmborg J, Harris J, Czene K, Havelick D, Scheike T . Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. JAMA. 2016; 315(1):68-76. PMC: 5498110. DOI: 10.1001/jama.2015.17703. View

14.

Vieira A . Basis of Inheritance in Humans. Monogr Oral Sci. 2022; 30:1-19. DOI: 10.1159/000520765. View

15.

Baldia P, Maurer A, Heide T, Rose M, Stoehr R, Hartmann A . Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup. Oncotarget. 2016; 7(44):71429-71439. PMC: 5342089. DOI: 10.18632/oncotarget.12198. View

16.

Vlachostergios P, Faltas B . Treatment resistance in urothelial carcinoma: an evolutionary perspective. Nat Rev Clin Oncol. 2018; 15(8):495-509. DOI: 10.1038/s41571-018-0026-y. View

17.

Zaghloul M, Zaghloul T, Bishr M, Baumann B . Urinary schistosomiasis and the associated bladder cancer: update. J Egypt Natl Canc Inst. 2020; 32(1):44. DOI: 10.1186/s43046-020-00055-z. View

18.

Sjodahl G, Eriksson P, Patschan O, Marzouka N, Jakobsson L, Bernardo C . Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma. Int J Cancer. 2019; 146(9):2636-2647. PMC: 7079000. DOI: 10.1002/ijc.32737. View

19.

Powles T, Duran I, van der Heijden M, Loriot Y, Vogelzang N, De Giorgi U . Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2017; 391(10122):748-757. DOI: 10.1016/S0140-6736(17)33297-X. View

20.

Nassar A, Abou Alaiwi S, AlDubayan S, Moore N, Mouw K, Kwiatkowski D . Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. Genet Med. 2019; 22(4):709-718. PMC: 7118025. DOI: 10.1038/s41436-019-0720-x. View